Eliquis (Apixaban) is a prescription anticoagulant medication designed to prevent and treat blood clots. Each tablet contains 2.5 mg of Apixaban, a direct factor Xa inhibitor that effectively reduces the risk of thromboembolic events.
Key Features:
- Mechanism of Action: Apixaban selectively inhibits factor Xa, an essential enzyme in the coagulation pathway. By blocking this enzyme, Eliquis helps prevent the formation of blood clots, thereby reducing the risk of stroke in patients with non-valvular atrial fibrillation and other conditions.
- Indications: Eliquis is indicated for:
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
- Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Dosage: Follow your healthcare provider’s instructions for dosage and duration of treatment. Dosage may vary based on factors such as age, renal function, and risk of bleeding.
- Administration: The tablets are taken orally, with or without food. It’s important to take them at the same time each day to maintain even levels of the medication in your bloodstream.
- Side Effects: Common side effects may include bleeding, bruising, nausea, and liver enzyme elevations. Contact your healthcare provider if you experience any unusual bleeding or severe side effects.
- Precautions: Not suitable for individuals with active bleeding or severe hypersensitivity to Apixaban. Always inform your healthcare provider of your complete medical history, including any other medications you are taking.
Storage: Store at room temperature, away from moisture and heat. Keep out of reach of children.
Note: Eliquis should be used under the supervision of a healthcare professional. Adhere strictly to the prescribed treatment regimen and consult your doctor with any questions or concerns regarding your health.
Disclaimer: This description is for informational purposes only and is not intended to provide medical advice or substitute for professional consultation.
Reviews
There are no reviews yet.